This preclinical study shows how the inability of engineered T cell therapies to eradicate solid tumors can be overcome by enabling antigen-independent stroma destruction along with antigen-specific tumor cell targeting, providing possible insights into how to dramatically expand the use of these therapies beyond circulating blood tumors where they are currently useful.
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Adoptive T cell therapy using chimeric antigen receptor-modified T cells (CAR-T therapy) has shown dramatic efficacy in patients with circulating lymphoma.
However, eradication of solid tumors with CAR-T therapy has not been reported yet to be efficacious. In solid tumors, stroma destruction, due to MHC-restricted crosspresentation of tumor antigens to T cells, may be essential. However, CAR-Ts recognize antigens in an MHC-independent manner on cancer cells but not stroma cells. In this report, we show how CAR-Ts can be engineered to eradicate large established tumors with provision of a suitable CD28 costimulatory signal. In a HER-2-dependent tumor model, tumor rejection by HER-2-specific CAR-Ts was associated with sustained influx and proliferation of the adoptively transferred T cells.
Interestingly, tumor rejection did not involve NK cells, but was associated instead with a marked increase in the level of M1 macrophages and a requirement for IFNγ receptor expression on tumor stroma cells. Our results argue that CAR-T therapy is capable of eradicating solid tumors through a combination of antigen-independent stroma destruction and antigen-specific tumor cell targeting.
Precis
This preclinical study shows how the inability of engineered T cell therapies to eradicate solid tumors can be overcome by enabling antigen-independent stroma destruction along with antigen-specific tumor cell targeting, providing possible insights into how to dramatically expand the use of these therapies beyond circulating blood tumors where they are currently useful.
Introduction
T cells can be redirected with new antigen specificity and used for adoptive T cell therapy (ATT) by introducing either a T cell receptor (TCR), or chimeric antigen receptor (CARs). The CAR consists of an antigen (Ag)-binding single chain variable fragment (scFv) antibody domain and a signaling domain, most often the CD3ζ endodomain (1) . While T cells with CARs (CAR-Ts) containing CD3ζ had a moderate anti-tumor effect and poor persistence in vivo (2) , addition of costimulatory signals as provided by dual signaling domains (e.g. CD28-CD3ζ) has improved the therapeutic effects of CAR-Ts in experimental models (3) and in clinical trials targeting CD19 on B cell malignancies (4, 5) .
Tumor transplantation models can be of clinical relevance if large established tumors grown for at least two weeks are treated (6) . Such solid tumors are difficult to reject, but can be successfully eradicated if the target antigen is recognized through the TCR (7) (8) (9) (10) (11) . On the other hand, CAR-mediated recognition leads to regression but not complete eradication (3) . This could be due to the sub-optimal affinity of the CAR to the target antigen or the different mode of antigen recognition of CARs versus TCRs. In contrast to TCRs, which recognize peptide antigen presented by MHC class I (MHC I), CARs recognize the cognate cell surface antigen by an antibody domain independently of the MHC I. This can be an advantage since tumors escape TCR-mediated ATT by MHC I down-regulation (12) , but it can also be a disadvantage because tumor stroma cells cross-presenting surrogate tumor antigen on MHC I needs to be recognized by T cells in order to prevent tumor escape (7) .
However, it appears that direct recognition of the tumor stroma is less important for tumor rejection if cancer-driving antigens (CDAs) are targeted by TCR-mediated ATT (10, 11) . CDAs are arguably the best targets because cancer cell proliferation/survival often depends on its continuous expression, as is the case for the human cell line SKOV3 and HER-2 (epidermal growth factor receptor-2) (13), which is termed oncogene addiction (14) . HER-2 is normally an overexpressed self-antigen, but in 4 this study we utilized a mouse model where human HER-2 was expressed only on the SKOV3 tumor cells and not on mouse cells, which makes it a relevant model for tumor-specific antigens targetable by CAR-Ts (e.g. mutant epidermal growth factor receptor (EGFRvIII) or the chaperon Cosmc) (15, 16) .
Previous studies employing CARs for treatment of xenografted solid human tumors used polyclonal human T cells as recipient cells for the CAR (3, 17) , a model containing several confounding factors ( Supplementary Fig. S1 ). Human CAR-Ts were allogeneic with regard to the tumor and xenogeneic with regard to the host. In this setting, it is difficult to exclude allo-MHC T cell responses (through the TCR) contributing to therapy effects. Conversely, lack of overt graft-versus-host reactions to the xenogeneic mouse tissues indicates that human T cells perform poorly in mice.
An unknown number of species-specific factors necessary for survival and proliferation may impair the function of human T cells in mice. For example, IFNγ function is species-specific (18), so that human T cell-derived IFNγ cannot act on mouse tumor stroma cells, which had been shown in syngeneic models to be critical in order to prevent tumor recurrence (8, 11) . To avoid confounding factors with polyclonal human T cells in mice and better dissect the mechanism of tumor eradication by CAR-Ts, we used mouse monoclonal CD8 + T cells with tumorunrelated specificity as CAR recipients (OVA-specific OT-1 cells derived from Rag -/-mice). This ensured that the CAR-Ts could act only through their CAR but not TCR, that IFNγ could act on the tumor stroma but not the human cancer cells and also excluded a potential contribution of CD4 + T cells on the therapeutic outcome ( Supplementary Fig. S1 ). Here, we first established that eradication of large established tumors can be achieved by HER-2-specific CAR-Ts if provided with costimulatory CD28 signaling (28-ζ-CAR) (19) . This rejection was associated with sustained accumulation, proliferation and differentiation of CAR-Ts to effector memory (TEM) cell type at the tumor site. We finally demonstrated that tumor 5 rejection by CAR-Ts involved destruction of tumor stroma through IFNγR, independently of NK cell contribution.
Materials and Methods

Mice
All mouse studies were in accordance with institutional, state, and federal 
Retroviral vectors and cells
HER-2 specific ζ-CARs constructs with scFv of different affinities and the 9-28-ζ-CAR of the intermediate affinity (20) were introduced into the MSCV expression plasmid as earlier described (21) . pMSCV vector encoding for GFP (pMIG) was used as mock control. Retroviral supernatants were generated by cotransfecting HEK-T cells with different MSCV-CAR constructs and gag, pol and env encoding pCL-eco vector (Imgenex) as described previously (21) . Virus supernatants were collected 48 and 72h post transfection and used for transducing T cells. Human ovarian carcinoma cell line SKOV3 expressing CBG luciferase was described earlier (21) . It was authenticated by flow cytometry as described below. 
Tumor digestion and cytokine release assay
A third or a half of the isolated tumor was sliced into small pieces and incubated for 1 hour at 37°C in 10 ml digestion solution (complete RPMI medium with collagenase II (1 mg/ml, Gibco), Dispase II (1 mg/ml, Roche) and DNAse I (10 μg/ml, Roche). 
Tumor challenge and adoptive T cell transfer
Age and sex matched mice were injected with 5x10 6 SKOV3-CBG tumor cells subcutaneously. On the day of treatment mice received i.v. injection of (unless otherwise indicated) 2x10 6 CAR-Ts or mock T cells, resuspended in 100 μl PBS. 
Bioluminescence imaging
In vivo imaging was performed using a Xenogen IVIS 200 (Caliper Lifescience). A maximum of five anaesthetized mice were imaged at once. Each mouse received an i.v. injection of freshly prepared coelenterazine (Biosynth) that was dissolved in DMSO (Sigma) and diluted in PBS (100 μg/100 μl per mouse) as earlier described (9) . Images were acquired for 1 min using small binning, unless saturated signal was obtained, in which case the acquisition was repeated using 10s imaging time. All data were analyzed using Living Image analysis software (Caliper Lifescience). The region of interest (ROI) for the measured signal was drawn at the tumor site identically for all mice and was set anew for each experiment.
Results
Increasing the affinity of a ζ-CAR does not improve the T cell function
HER-2 specific CARs were cloned into the pMSCV retroviral vector resulting in five (22) or the chimeric CD28-ζ receptor (19) . Accordingly, we found that CAR-Ts engineered with 9-28-ζ but not ζ-CARs secreted IL-2 ( Figure   1C ).
We next investigated the ability of ζ-CAR-Ts to reject SKOV3 tumors in vivo and whether an increase in scFv affinity influences therapeutic outcome. Rag -/-mice were subcutaneously (s.c.) injected with 5x10 6 SKOV3 cells. About 3 weeks later when the tumors were 6.6 mm (SD ± 1.1 mm) in average diameter, the mice were treated intravenously (i.v.) with 2x10 6 CAR-Ts transduced with mock (GFP) retrovirus or the different affinity ζ-CARs. Tumors in mice that received 7-ζ-CAR-Ts progressed unimpaired comparable to mock-treated mice ( Figure 2 and Table 1 ). Similarly, ζ-CAR-Ts of the other affinities (including the highest affinity 11-ζ-CAR) did not reject SKOV3 tumors and, if at all, only slightly delayed tumor progression ( Figure 2 and Table 1 ).
Costimulation by the 28-ζ-CAR leads to rejection of large established tumors
To determine if addition of an costimulatory CD28 signaling to the CAR molecule would lead to rejection of SKOV3 tumors, tumor-bearing mice were treated with CAR-Ts expressing either 9-ζ-or 9-28-ζ-CAR, which contain the same scFv domain (KD: 1x10 -9 M) but different signaling domains. As before, tumors grown for ∼3 weeks (average tumor diameter 7.1 mm, SD ± 0.4 mm) progressed in mice receiving 9-ζ-CAR-Ts or mock treatment, but were long-term rejected by 9-28-ζ-CAR-Ts (mice remained tumor free 60 days post rejection) ( Figure 3A and Figure 3B and Table 1 ). To further confirm these results, mice with large established tumors (average tumor diameter 10.5 mm, SD ± 1.8 mm) received the same number of CAR + T cells; either mock treated or injected with 2x10 6 CAR-Ts with similar percentage of 9-28-ζ-or 9-ζ-CAR + cells (8% and 10%, respectively). Once again, 9-28-ζ-CAR-Ts rejected the tumors (n=2), while tumors in mock-treated and 9-ζ-CARTs treated mice progressed ( Figure 3C and Table 1 ). 
CAR-Ts
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Using BLI, we observed that 9-28-ζ-CAR-Ts expanded in the tumor-bearing mouse and accumulated preferentially at the tumor site ( Supplementary Fig. S4 ). Although BLI allowed us to visualize this accumulation, we could not address the question of whether these cells were also able to proliferate inside the tumor or to evaluate their differentiation status. Since retroviral transduction required antigen-independent T cell activation, 9-ζ-CAR-, 9-28-ζ-CAR-and mock-transduced CAR-Ts contained similar numbers of similarly activated T cells. This was confirmed by the high (hi) expression of CD44 and CD62L (CD44hi, CD62Lhi, Figure 5A 
CAR-mediated rejection depends on IFNγR expression on the tumor stroma
By analyzing the tumors for the cancer cells and stroma cells content, we found that large established SKOV3 tumors contained ∼15% of HER-2 + cancer cells while the other 85% were stroma cells ( Supplementary Fig. S5A ). The majority of the stroma cells in the SKOV3 tumors were of non-hematopoietic origin (>90% CD45.2 negative, Supplementary Fig. S5A ). To investigate whether CAR-mediated tumor rejection requires targeting of the tumor stroma by IFNγ, we treated Rag -/-and IFNγR -/-/Rag -/-mice bearing ∼3 weeks old SKOV3 tumors (6.6 mm; SD ± 1.5 mm) with mock or 9-28-ζ-CAR-Ts. In Rag -/-mice, tumors were again rejected following treatment with 9-28-ζ-CAR-Ts ( Figure 6A and Table 1 ). However, following treatment with 9-28-ζ-CAR-Ts, tumors progressed in IFNγR -/-/Rag -/-mice at a comparable kinetic to that seen in mock-treated mice ( Figure 6A and Table 1 ).
In Nevertheless, macrophages in tumors from 9-28-ζ-CAR-T treated mice had a marked increase in MHC class II expression (80%) which is typical for M1 macrophage population, while the percentages were much lower for 9-ζ-CAR-T (43%) and mock (28%) treated mice ( Figure 6C ). These findings indicate that the IFNγ secreted by 9-28-ζ-CAR-Ts activated NK cells and M1 macrophages. To investigate the role of NK cell activation in tumor rejection, we performed an in vivo NK cell depleting experiment. Tumor bearing mice received a-NK 1.1 antibody or isotype (iso) control weekly over the period of 85 days (starting two days before ATT) which depleted the NK cells in the blood (Supplementary Fig. S5B ). Mock treated mice did not receive any additional treatment and tumors progressed ( Figure 6D ).
Mice that were treated with a-NK 1.1 antibody and isotype control received 9-28-ζ-CAR-Ts, and during the observation time of 82 days post ATT majority of the tumors were rejected for both groups (2/3 for isotype control and 4/5 for NK depleted) ( Figure 6D ). This indicates that NK cells were not necessary for the CAR-mediated tumor rejection.
Discussion
Our study showed for the first time that CAR-Ts were able to reject large solid tumors exclusively by CAR-mediated CD8 + T cell effector function and independent of CD4 Both antigen-dependent and -independent mechanisms can contribute to stroma destruction as a requirement for cancer eradication (27) . Previous studies of TCRmediated ATT consistently reported that tumor stroma targeting was critical to prevent tumor recurrence and that T cell-produced IFNγ needed to act on the tumor stroma (8, 11) . However, likely due to the use of different experimental models, different mechanisms were suggested to explain this. When using a surrogate antigen expressed at a high level, antigen cross-presentation by stroma cells was essential for bystander elimination of antigen loss variants (7, 8) , while targeting a CDA (like SV40 large T antigen) did not require antigen cross-presentation for tumor eradication in a H-2 mismatched host (10, 11) . Excluding that cross-dressing by the peptide-MHC (28) could have contributed to stroma recognition in the H-2 mismatched host, it appeared but was not formally proven that antigen recognition only on the cancer cells was sufficient for tumor rejection. This could have resulted from the induction of IFNγ production by the T cells, which then acted on stroma cells in an antigen-independent fashion either by direct stroma destruction or indirectly by activating the non T cell immune compartment (10, 11, 29, 30) . We proved the initial assumption in our current study because CAR-Ts recognized HER-2 exclusively on the cancer cells but not tumor stroma, yet IFNγ responsiveness by the stroma was essential for tumor rejection. There was a correlation between increase in the M1 macrophage numbers and tumor rejection in our model, however, it is not clear whether the macrophages directly contributed to tumor rejection, or whether simply the increase was due to higher number of T cells secreting IFNγ in the tumors.
Similarly, IFNγ led to NK cell activation, but despite the increased numbers of NK cell infiltrates in tumors of 28-ζ-CAR-T treated mice, the CAR-mediated tumor rejection was not dependent on NK cells. In accordance with our previous studies (10, 31) , it is possible that the mechanism of IFNγ acting on tumor stroma has a direct effect involving destruction of tumor vasculature. However, we cannot completely exclude Due to species-specific binding, the IFNγ secreted by the mouse T cells could only act on the tumor stroma but not on the cancer cells, which might explain the prolonged rejection time required in our model. Simultaneous cancer and stroma cell targeting would have probably accelerated tumor rejection, as is the case in other models where both tumor compartments were targeted by IFNγ (7,9,10).
Furthermore, the inability of 9-28-ζ-CAR-Ts therapy to induce initial tumor regression in IFNγR -/-/Rag -/-mice could be attributed to this specific setting, in which both cancer and stroma cells were not responsive to IFNγ (11) .
Although targeting stroma cells by IFNγ was essential for tumor rejection in our model, we cannot exclude that stroma cell targeting would have been dispensable in a setting where also cancer cells responded to IFNγ. However, in the cases when human CAR-Ts were used for therapy and cancer cells responded to IFNγ, established tumors could not be completely rejected (3, 17) , further implying at the relevance of IFNγ-stroma cell targeting for tumor rejection. Therefore, it will be important in future studies to elucidate the relative contribution of antigen-dependent (7, 8) and -independent (10,11) destruction of tumor stroma and whether our data are related to targeting a CDA.
Despite the effectiveness of tumor rejection by 9-28-ζ-CAR, we do not suggest using HER-2-CARs in the clinic, because we did not address potential toxicity in regard to HER-2 expression on normal cells. However, our data are clinically relevant because tumor-specific antigens accessible for CARs have been described (15, 16) and will be evaluated for clinical use (33) . Taken together, our results show that antigenindependent tumor stroma destruction is required for CAR-mediated cancer eradication. The average expression for ζ-CARs was 6% (SD ± 3%) and 5% for the 9-28-ζ-CAR. . Two days before ATT mice were treated with either a-NK 1.1 (n=5) or isotype control (iso) (n=3) Ab, which was followed by weekly Ab administration throughout the duration of the experiment.
Mock treated mice (n=2) did not receive Ab treatment. Indicated are mean tumor diameters of individual mice over time from a single experiment. 
